Bacterial Pneumonia

Subscribe to Selected New Research on Bacterial Pneumonia

575 relevant articles (38 outcomes, 63 trials/studies) found for this Disease

Description: Inflammation of the lung parenchyma that is caused by bacterial infections.

Also Known As:

Pneumonia, Bacterial; Bacterial Pneumonias; Pneumonias, Bacterial

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Pneumonia (Pneumonitis)
2.	Acute Lung Injury
3.	Infection
4.	Chronic Bronchitis
5.	Sepsis (Septicemia)

Experts

1.	Asaoka, Naoko: 3 articles (06/2006 - 03/2002)
2.	Honda, Yoshihiro: 3 articles (06/2006 - 03/2002)
3.	Okimoto, Niro: 3 articles (06/2006 - 03/2002)
4.	Ohba, Hideo: 3 articles (06/2006 - 03/2002)
5.	McCullers, Jonathan A: 2 articles (01/2008 - 07/2005)
6.	Yamato, Kenji: 2 articles (06/2006 - 10/2004)
7.	Osaki, Kohichi: 2 articles (06/2006 - 10/2004)
8.	Kurihara, Takeyuki: 2 articles (06/2006 - 10/2004)
9.	Fujita, Kazue: 2 articles (10/2004 - 03/2002)
10.	Tasaka, Sadatomo: 2 articles (01/2003 - 07/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Bacterial Pneumonia:

1.	Amoxicillin (Wymox)FDA LinkGeneric 10/01/1998 - "OBJECTIVE: To determine if intramuscular (IM) penicillin is more effective than oral (PO) amoxicillin in the early outpatient treatment of pediatric patients with presumed bacterial pneumonia. " 03/01/1986 - "[A double blind comparative study on the efficacy of S6472, cefaclor and amoxicillin, in the treatment of bacterial pneumonia]" 10/01/1998 - "CONCLUSION: There does not appear to be a significant difference between PO amoxicillin and IM penicillin in the early outpatient treatment of pediatric patients with presumed bacterial pneumonia." 06/01/1998 - "Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia." 01/01/1989 - "One hundred children with clinically diagnosed bacterial pneumonia were assigned at random to receive treatment with either amoxycillin (250 or 500 mg) or amoxycillin (250 or 500 mg) plus clavulanic acid (62.5 or 125 mg) 3-times daily, dosage and duration of treatment being determined by the severity of the condition. " Order ALL the reference details at left...
2.	Cefaclor (Ceclor)FDA LinkGeneric 03/01/1986 - "From these results of this trial, it is concluded that oral administration of 750 mg of S6472 twice a day (1,500 mg per day) is as effective and useful as that of 500 mg of ordinary CCL 3 times a day (1,500 mg per day) or 500 mg of AMPC 4 times a day (2,000 mg per day) in the treatment of bacterial pneumonia or lung abscess." 03/01/1986 - "[A double blind comparative study on the efficacy of S6472, cefaclor and amoxicillin, in the treatment of bacterial pneumonia]" 11/01/1988 - "[Comparative clinical study of CS-807 and cefaclor for bacterial pneumonia by a double-blind method]" 10/01/1991 - "Azithromycin versus cefaclor in the treatment of acute bacterial pneumonia." 11/01/1990 - "The efficacy, safety and usefulness of BMY-28100 for the treatment of bacterial pneumonia were compared with those of cefaclor (hereinafter referred to as CCL) in a double-blind study. " Order ALL the reference details at left...
3.	Anti-Bacterial Agents (Antibiotics)IBA 06/01/2009 - "Administration of antibiotics was started because bacterial pneumonia was suspected. " 03/01/2009 - "CONCLUSIONS: Mortality remains unacceptably high in immunocompetent patients admitted to the ICU with bacterial pneumonia, despite adequate initial antibiotics and comorbidities management. " 01/01/2009 - "As a chest X-ray showed infiltrates of the right lung, he was diagnosed as bacterial pneumonia and treated with antibiotics. " 01/01/2009 - "He was given a diagnosis of bacterial pneumonia and was treated with several antibiotics. " 12/01/2008 - "The US Food and Drug Administration is reviewing its criteria for evaluating new antibiotics for the treatment of bacterial pneumonia. " Order ALL the reference details at left...
4.	loracarbef (Lorax)FDA Link 06/22/1992 - "Thus, these clinical trials support the conclusion that loracarbef is a safe and effective treatment for bacterial pneumonia." 06/22/1992 - "Loracarbef, a member of the carbacephem class of antibiotics, was tested in a series of clinical trials for its efficacy and safety in the treatment of lobar and bronchial bacterial pneumonia. " 03/01/1992 - "It is concluded that both loracarbef and amoxicillin/clavulanate are safe and effective in the treatment of acute bacterial pneumonia." Order ALL the reference details at left...
5.	Penicillins (Penicillin)FDA Link 09/01/2001 - "pneumoniae are often lethal and justify the penicillin prophylaxis, which has provided a dramatic decrease in early mortality bacterial pneumonia is common in patients younger than four years, with most cases being due to S. " 10/01/1996 - "The continuing emergence of antibiotic-resistant bacteria (e.g., penicillin-resistant pneumococci) suggests that bacterial pneumonia will assume increasing importance in the coming years. " 03/01/1995 - "PATIENTS: This evaluation was based on a consecutive sample of 1822 adult patients (> 18 years of age) with documented or suspected bacterial pneumonia who were being treated with a cephalosporin, a penicillin, or an aminoglycoside over a 3-month period. " 04/01/1994 - "INCLUSION AND EXCLUSION CRITERIA: A total of 1822 adult patients with documented or suspected bacterial pneumonia who were receiving a cephalosporin, penicillin, or an aminoglycoside were enrolled. " 12/01/1985 - "The lower incidence of bacterial pneumonias among our patients compared with that previously reported may reflect our use of penicillin prophylaxis and pneumococcal immunization to prevent S. " Order ALL the reference details at left...
6.	Clavulanic Acid (Potassium Clavulanate)FDA LinkGeneric 01/01/1989 - "One hundred children with clinically diagnosed bacterial pneumonia were assigned at random to receive treatment with either amoxycillin (250 or 500 mg) or amoxycillin (250 or 500 mg) plus clavulanic acid (62.5 or 125 mg) 3-times daily, dosage and duration of treatment being determined by the severity of the condition. " 03/01/1992 - "It is concluded that both loracarbef and amoxicillin/clavulanate are safe and effective in the treatment of acute bacterial pneumonia." 01/01/1989 - "An open, comparative evaluation of amoxycillin and amoxycillin plus clavulanic acid ('Augmentin') in the treatment of bacterial pneumonia in children." 01/01/2001 - "Sequential i.v./oral amoxicillin-clavulanate and parenteral ceftriaxone were equally safe and effective for the empirical treatment of acute bacterial pneumonia, including penicillin and cephalosporin-resistant pneumococcal pneumonia. " Order ALL the reference details at left...
7.	cefepime (Maxipime)FDA LinkGeneric 07/01/1992 - "[A comparative study of cefepime for bacterial pneumonia]" 08/01/2003 - "OBJECTIVE: To determine the steady-state plasma and epithelial lining fluid concentrations of cefepime administered in continuous infusion in critically ill patients with severe bacterial pneumonia. " 10/01/2001 - "Cefepime versus cefotaxime for empirical treatment of bacterial pneumonia in HIV-infected patients: an open, randomized trial." 06/24/1996 - "The purpose of these studies was to compare the efficacy and safety of the fourth-generation agent, cefepime, with that of the third-generation agent, ceftazidime, in the treatment of hospitalized patients with moderate-to-severe bacterial pneumonia. " 07/01/1992 - "The efficacy, safety and usefulness of cefepime (CFPM), a new cephem antibiotic, in bacterial pneumonia, were evaluated in a comparative study against ceftazidime (CAZ). " Order ALL the reference details at left...
8.	Ceftazidime (Fortum)FDA LinkGeneric 08/01/1997 - "As suggested by the evaluation on the secondary endpoint in the phase III comparative studies with both bacterial pneumonia and chronic respiratory tract infections, it was confirmed that the 7 day therapy of CFLP was promising for treatment of moderate bacterial pneumonia and chronic respiratory tract infections, because the high clinical efficacy was obtained and also the incidence of allergic reactions with CFLP was almost the same as that of ceftazidime (CAZ) evaluated highly safe. " 06/24/1996 - "The purpose of these studies was to compare the efficacy and safety of the fourth-generation agent, cefepime, with that of the third-generation agent, ceftazidime, in the treatment of hospitalized patients with moderate-to-severe bacterial pneumonia. " 07/01/1992 - "The efficacy, safety and usefulness of cefepime (CFPM), a new cephem antibiotic, in bacterial pneumonia, were evaluated in a comparative study against ceftazidime (CAZ). " 08/01/1998 - "Forty patients with severe infections including septicemia, urinary tract infection and bacterial pneumonia were randomly assigned to receive treatment with cefepime (2 g intravenously every 12 h) or ceftazidime (2 g intravenously every 8 h). " 09/01/2002 - "An open-label, randomized study was conducted to evaluate the safety and efficacy of cefepime versus ceftazidime in the treatment of severe bacterial infections, including septicemia, urinary tract infection, bacterial bronchitis, bacterial pneumonia, and intraabdominal infection. " Order ALL the reference details at left...
9.	dirithromycin (Dynabac)FDA Link 03/01/1994 - "We conclude that dirithromycin, 500 mg, once daily, is safe and effective in the treatment of community-acquired bacterial pneumonia. " 03/01/1994 - "Dirithromycin, a new once-daily macrolide, was studied in a multicentre, randomised, double-blind trial in community-acquired bacterial pneumonia. " 03/01/1993 - "In a double-blind, double-dummy, multicentre study the efficacy and safety of dirithromycin 500 mg/day given orally once daily for 10-14 days were compared with those of erythromycin 1000 mg/day given orally four times daily for 10-14 days in patients with bacterial pneumonia. " 03/01/1994 - "A comparative study of dirithromycin and erythromycin in bacterial pneumonia." Order ALL the reference details at left...
10.	procalcitoninIBA 07/01/2007 - "To measure procalcitonin values accurately in the primary care setting, a more sensitive method is needed, but there was no indication that procalcitonin is superior to CRP in identifying patients with pneumonia, bacterial aetiology, or adverse outcome." 12/01/2008 - "Among the important novel developments ranks the analysis of serum procalcitonin for a better identification and treatment monitoring of bacterial pneumonias compared to conventional tests and a simple scoring system, like the CRB-65/CURB score, for a rapid risk stratification. " 01/01/2003 - "Serum procalcitonin concentrations in bacterial pneumonia in children: a negative result in primary healthcare settings." 07/01/2007 - "CONCLUSION: Both procalcitonin >0.06 ng/ml and CRP > or =20 mg/l were associated with radiographic pneumonia, bacterial infection, and subsequent hospitalisation, but positive predictive values were too low for any of the two inflammatory markers to be of use in clinical practice. " 07/01/2007 - "In predicting radiographic pneumonia, bacterial infection, and hospitalisation, the sensitivities of procalcitonin >0.06 ng/ml were 0.70, 0.51, and 0.67, and of CRP were > or =20 mg/l, 0.73, 0.56, and 0.74 respectively. " Order ALL the reference details at left...

Therapies and Procedures

1.	Artificial Respiration (Mechanical Ventilation) 05/01/2006 - "PATIENTS: Thirteen adult patients with nosocomial bacterial pneumonia on mechanical ventilation were enrolled. " 04/01/2005 - "The aim of our review was to evaluate up to date facts regarding control of bacterial pneumonias during mechanical ventilation in intensive care unit settings." 04/01/2005 - "Control of bacterial pneumonia during mechanical ventilation." 05/01/2004 - "PATIENTS: Ten adult patients with severe nosocomial bacterial pneumonia on mechanical ventilation. " 05/01/2004 - "PATIENTS: A total of 15 adult patients with severe nosocomial bacterial pneumonia on mechanical ventilation were enrolled. " Order ALL the reference details at left...
2.	Drug Therapy (Chemotherapy) 07/01/2009 - "DLTs included febrile neutropaenia, thrombocytopaenia, bacterial pneumonia and delayed second cycle of chemotherapy. " 08/01/1993 - "We measured neutrophil's CL (CL-index) in 12 patients of the bacterial pneumonia three times per each case: before, during and after chemotherapy. " 08/01/1993 - "I: Change in neutrophil's CL by chemotherapy against the bacterial pneumonia]" 01/01/1982 - "[Chemotherapy of acute bacterial pneumonia]" 10/01/1977 - "[Chemotherapy of bacterial pneumonia]" Order ALL the reference details at left...
3.	Transplants (Transplant) 01/01/1999 - "BACKGROUND: We present the case of a 12-year-old female with severe postoperative bacterial pneumonia unresponsive to conventional treatment following a failed renal transplant. " 05/01/1998 - "On day +6 after peripheral blood stem cell transplant (PBSCT) bacterial pneumonia developed. " 06/01/1992 - "Late bacterial pneumonia may occur more than 6 months after transplant because of prolonged immunedeficiency and functional asplenia. " 03/01/1990 - "The incidence of bacterial pneumonia is highest in recipients of heartlung (22%) and liver transplants (17%), intermediate in recipients of heart transplants (5%), and lowest in renal transplant patients (1 to 2%). " 05/01/2002 - "PURPOSE: Bacterial pneumonia has been cited as the leading cause of infectious death in renal transplant recipients but has not been studied in a national transplant population. " Order ALL the reference details at left...
4.	Endoscopes 04/01/1997 - "Paediatric and neonatal intensive care units have benefited from the availability in the market of these small endoscopes for 3.5 and 2.2 mm. The protected brush and alveolar lavage (LBA) enables a specific diagnosis to be made in bacterial pneumonia acquired during ventilation. " Order ALL the reference details at left...
5.	Highly Active Antiretroviral Therapy (HAART) 11/01/2000 - "The aim of the study was to assess the incidence of hospital and community acquired bacterial pneumonia in HIV-infected subjects prior to and after the introduction of highly active antiretroviral therapy (HAART). " 01/01/2009 - "Age (p = 0.04), pack-year smoking history (p<0.001), previous bacterial pneumonia (p = 0.007), and HAART use (p = 0.04) were independent predictors of decreased FEV(1)/FVC. " 07/01/2004 - "Although not yet fully evaluated in Africa, based on experience in industrialised nations, use of HAART in Africa may have substantial potential to prevent bacterial pneumonia." 06/01/2004 - "One patient, who discontinued HAART, contracted a fatal bacterial pneumonia. " 04/01/2004 - "Only in patients with a baseline CD4+ T cell count lower than 200/microl and immunological response to HAART, a near significant lower incidence of all bacterial pneumonia was observed after vaccination. " Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Bacterial Pneumonia

*WARNING* This specific disease subtype has a relatively small number of significant evidence outcomes. You may proceed to order anyway, or go back to the search field and enter a more general type of the target illness. Once your report has been ordered, however, we can't refund the purchase.

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 38 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>